
Opinion|Videos|August 7, 2024
EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer
Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Practical uses of AI across the urologic care continuum
2
Study progresses of nogapendekin alfa inbakicept for BCG-naïve NMIBC
3
The UroOnc Minute: Diet and Prostate Cancer, with Stephen J. Freedland, MD
4
Walter Hsiang, MD, discusses insurance-related barriers to kidney stone care
5






















